Du Pont has begun the process of weeding out suitors for its medicalproducts business, according to the Wilmington, DE, company. Thefirm is sending out information on its medical products unitsto companies that it believes are qualified to buy the
Du Pont has begun the process of weeding out suitors for its medicalproducts business, according to the Wilmington, DE, company. Thefirm is sending out information on its medical products unitsto companies that it believes are qualified to buy the businesses,according to spokesperson Jayne Seebach Persico.
Industry speculation has run rampant as to the identity of abuyer for the units, which include the Du Pont Diagnostic Imagingfilm and digital imaging business. Some observers have suggestedthat a buyer has already been found, but those pundits are jumpingthe gun, Persico said.
"The field has been narrowed, but we do not have a buyerat this time," Persico said.
We don't anticipate selling or having a firm idea of who thebuyer is until the (Radiological Society of North America meeting).
Du Pont received 60 to 80 inquiries in the weeks after it announcedit was selling the medical products business to pay for the purchaseof its stock held by Seagram (SCAN 6/7/95). The company is determiningwhich of those candidates are qualified to continue in the process,which will require the signing of a confidentiality agreementbefore interested parties can receive additional information onthe medical products business.
Among the criteria Du Pont is using to size up potential buyersare the strategic business fit between Du Pont and the acquiringcompany, whether antitrust issues would interfere with an acquisition,and the company's treatment of employees and customers. Du Ponthopes to have the deal completed by early 1996, Persico said.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.